1
|
Özgüden-Akkoc CG, Mutlu AM, Keskin A, Yumuşak E, Akkoc A. Phenotypic evaluation of mast cells in bovine mammary tissue and mastitis in the context of fibrosis. J DAIRY RES 2023; 90:387-392. [PMID: 38186214 DOI: 10.1017/s0022029923000651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2024]
Abstract
This research paper addresses the hypothesis that mast cells (MCs) contribute to the formation of mammary fibrosis. MCs are important immune regulatory and immune modulatory cells that play major roles in the inflammatory process. Since there is no detailed knowledge, this research study aimed to comparatively investigate the presence, localization, and immunophenotypes of MCs in healthy and mastitic mammary tissues. A total of 264 mammary samples were evaluated for the examination of mast cells and fibrosis. The mean mast cell number in both acute and chronic mastitis samples were very significantly higher than the control group P < 0.001). A 7.9-fold increase in the number of mast cells was found when the chronic mastitis group was compared with the control (healthy) group. Immunohistochemistry revealed presence of all three immune phenotypes in control and mastitic mammary samples (tryptase + (MCT), chymase + (MCC) and both chymase and tryptase + (MCTC). The mean MCT, MCC, and MCTC numbers in the chronic mastitis group were found to be significantly higher than the control (P < 0.001 for all three phenotypes) but did not differ significantly between control and acute mastitis samples. When the mean numbers of MCT, MCC, and MCTC in the control group and chronic mastitis group were compared, a 10.5, 7.8, and a 4.1-fold increase was observed, respectively. The amount of connective tissue was strongly increased in tissues with chronic mastitis and a 3.01-fold increase was detected compared to the control group. A statistically significant relation was also found between the amount of fibrosis and the increased number of total MCs (P < 0.001).
Collapse
Affiliation(s)
- Cansel Güzin Özgüden-Akkoc
- Department of Histology & Embryology, Faculty of Veterinary Medicine, Bursa Uludağ University, Bursa, Turkey
| | - Ayşe Meriç Mutlu
- Department of Pathology, Health Sciences Institute, Bursa Uludağ University, Bursa, Turkey
| | - Abdülkadir Keskin
- Department of Gynaecology & Obstetrics, Faculty of Veterinary Medicine, Bursa Uludağ University, Bursa, Turkey
| | - Ezgi Yumuşak
- Department of Pathology, Health Sciences Institute, Bursa Uludağ University, Bursa, Turkey
| | - Ahmet Akkoc
- Department of Pathology, Faculty of Veterinary Medicine, Bursa Uludağ University, Bursa, Turkey
| |
Collapse
|
2
|
St John AL, Rathore APS, Ginhoux F. New perspectives on the origins and heterogeneity of mast cells. Nat Rev Immunol 2023; 23:55-68. [PMID: 35610312 DOI: 10.1038/s41577-022-00731-2] [Citation(s) in RCA: 38] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/25/2022] [Indexed: 01/06/2023]
Abstract
Mast cells are immune cells of the haematopoietic lineage that are now thought to have multifaceted functions during homeostasis and in various disease states. Furthermore, while mast cells have been known for a long time to contribute to allergic disease in adults, recent studies, mainly in mice, have highlighted their early origins during fetal development and potential for immune functions, including allergic responses, in early life. Our understanding of the imprinting of mast cells by particular tissues of residence and their potential for regulatory interactions with organ systems such as the peripheral immune, nervous and vascular systems is also rapidly evolving. Here, we discuss the origins of mast cells and their diverse and plastic phenotypes that are influenced by tissue residence. We explore how divergent phenotypes and functions might result from both their hard-wired 'nature' defined by their ontogeny and the 'nurture' they receive within specialized tissue microenvironments.
Collapse
Affiliation(s)
- Ashley L St John
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
- Department of Pathology, Duke University Medical Center, Durham, NC, USA.
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- SingHealth Duke-NUS Global Health Institute, Singapore, Singapore.
| | - Abhay P S Rathore
- Department of Pathology, Duke University Medical Center, Durham, NC, USA
| | - Florent Ginhoux
- Singapore Immunology Network, A*STAR, Singapore, Singapore.
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
| |
Collapse
|
3
|
Vibhushan S, Bratti M, Montero-Hernández JE, El Ghoneimi A, Benhamou M, Charles N, Daugas E, Blank U. Mast Cell Chymase and Kidney Disease. Int J Mol Sci 2020; 22:E302. [PMID: 33396702 PMCID: PMC7795820 DOI: 10.3390/ijms22010302] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 12/23/2020] [Accepted: 12/27/2020] [Indexed: 12/21/2022] Open
Abstract
A sizable part (~2%) of the human genome encodes for proteases. They are involved in many physiological processes, such as development, reproduction and inflammation, but also play a role in pathology. Mast cells (MC) contain a variety of MC specific proteases, the expression of which may differ between various MC subtypes. Amongst these proteases, chymase represents up to 25% of the total proteins in the MC and is released from cytoplasmic granules upon activation. Once secreted, it cleaves the targets in the local tissue environment, but may also act in lymph nodes infiltrated by MC, or systemically, when reaching the circulation during an inflammatory response. MC have been recognized as important components in the development of kidney disease. Based on this observation, MC chymase has gained interest following the discovery that it contributes to the angiotensin-converting enzyme's independent generation of angiotensin II, an important inflammatory mediator in the development of kidney disease. Hence, progress regarding its role has been made based on studies using inhibitors but also on mice deficient in MC protease 4 (mMCP-4), the functional murine counterpart of human chymase. In this review, we discuss the role and actions of chymase in kidney disease. While initially believed to contribute to pathogenesis, the accumulated data favor a more subtle view, indicating that chymase may also have beneficial actions.
Collapse
Affiliation(s)
- Shamila Vibhushan
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
| | - Manuela Bratti
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
| | - Juan Eduardo Montero-Hernández
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
| | - Alaa El Ghoneimi
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
- Department of Pediatric Surgery and Urology, Hôpital Universitaire Robert Debré, Assistance Publique—Hôpitaux de Paris (APHP), F-75019 Paris, France
| | - Marc Benhamou
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
| | - Nicolas Charles
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
| | - Eric Daugas
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
- Service de Néphrologie, Groupe Hospitalier Universitaire Bichat-Claude Bernard, Assistance Publique—Hôpitaux de Paris (APHP), F-75019 Paris, France
| | - Ulrich Blank
- Centre de Recherche sur l’inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France; (S.V.); (M.B.); (J.E.M.-H.); (A.E.G.); (M.B.); (N.C.); (E.D.)
- Laboratoire d’Excellence Inflamex, Université de Paris, F-75018 Paris, France
| |
Collapse
|
4
|
Abstract
Physical trauma can affect any individual and is globally accountable for more than one in every ten deaths. Although direct severe kidney trauma is relatively infrequent, extrarenal tissue trauma frequently results in the development of acute kidney injury (AKI). Various causes, including haemorrhagic shock, rhabdomyolysis, use of nephrotoxic drugs and infectious complications, can trigger and exacerbate trauma-related AKI (TRAKI), particularly in the presence of pre-existing or trauma-specific risk factors. Injured, hypoxic and ischaemic tissues expose the organism to damage-associated and pathogen-associated molecular patterns, and oxidative stress, all of which initiate a complex immunopathophysiological response that results in macrocirculatory and microcirculatory disturbances in the kidney, and functional impairment. The simultaneous activation of components of innate immunity, including leukocytes, coagulation factors and complement proteins, drives kidney inflammation, glomerular and tubular damage, and breakdown of the blood-urine barrier. This immune response is also an integral part of the intense post-trauma crosstalk between the kidneys, the nervous system and other organs, which aggravates multi-organ dysfunction. Necessary lifesaving procedures used in trauma management might have ambivalent effects as they stabilize injured tissue and organs while simultaneously exacerbating kidney injury. Consequently, only a small number of pathophysiological and immunomodulatory therapeutic targets for TRAKI prevention have been proposed and evaluated.
Collapse
|
5
|
Bivona BJ, Takai S, Seth DM, Satou R, Harrison-Bernard LM. Chymase inhibition retards albuminuria in type 2 diabetes. Physiol Rep 2020; 7:e14302. [PMID: 31872559 PMCID: PMC6928241 DOI: 10.14814/phy2.14302] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Chymase released from mast cells produces pro‐fibrotic, inflammatory, and vasoconstrictor agents. Studies were performed to test the hypothesis that chronic chymase inhibition provides a renal protective effect in type 2 diabetes. Diabetic (db/db) and control mice (db/m) were chronically infused with a chymase‐specific inhibitor or vehicle for 8 weeks. Baseline urinary albumin excretion (UalbV) averaged 42 ± 3 and 442 ± 32 microg/d in control (n = 22) and diabetic mice (n = 27), respectively (p < .05). After administration of chymase inhibitor to diabetic mice, the change in UalbV was significantly lower (459 ± 57 microg/d) than in vehicle‐treated diabetic mice (645 ± 108 microg/d). UNGALV was not different at baseline between diabetic mice that would receive the chymase inhibitor (349 ± 56 ng/d, n = 6) and vehicle (373 ± 99 ng/d, n = 6) infusions, but increased significantly only in the vehicle‐treated diabetic mice (p < .05). Glomeruli of diabetic kidneys treated chronically with chymase inhibition demonstrated reduced mesangial matrix expansion compared to glomeruli from untreated diabetic mice. Plasma angiotensin II levels were not altered by chymase inhibitor treatment. In summary, chronic chymase inhibition slowed the progression of urinary albumin excretion in diabetic mice. In conclusion, renal chymase may contribute to the progression of albuminuria in type 2 diabetes renal disease.
Collapse
Affiliation(s)
- Benjamin J Bivona
- Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Shinji Takai
- Department of Innovative Medicine, Osaka Medical College, Takatsuki City, Osaka, Japan
| | - Dale M Seth
- Department of Physiology, Tulane University School of Medicine, New Orleans, LA, USA
| | - Ryousuke Satou
- Department of Physiology, Tulane University School of Medicine, New Orleans, LA, USA
| | - Lisa M Harrison-Bernard
- Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| |
Collapse
|
6
|
Pejler G. Novel Insight into the in vivo Function of Mast Cell Chymase: Lessons from Knockouts and Inhibitors. J Innate Immun 2020; 12:357-372. [PMID: 32498069 DOI: 10.1159/000506985] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 03/03/2020] [Indexed: 12/14/2022] Open
Abstract
Mast cells are now recognized as key players in diverse pathologies, but the mechanisms by which they contribute in such settings are only partially understood. Mast cells are packed with secretory granules, and when they undergo degranulation in response to activation the contents of the granules are expelled to the extracellular milieu. Chymases, neutral serine proteases, are the major constituents of the mast cell granules and are hence released in large amounts upon mast cell activation. Following their release, chymases can cleave one or several of a myriad of potential substrates, and the cleavage of many of these could potentially have a profound impact on the respective pathology. Indeed, chymases have recently been implicated in several pathological contexts, in particular through studies using chymase inhibitors and by the use of chymase-deficient animals. In many cases, chymase has been shown to account for mast cell-dependent detrimental effects in the respective conditions and is therefore emerging as a promising drug target. On the other hand, chymase has been shown to have protective roles in other pathological settings. More unexpectedly, chymase has also been shown to control certain homeostatic processes. Here, these findings are reviewed.
Collapse
Affiliation(s)
- Gunnar Pejler
- Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden, .,Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden,
| |
Collapse
|
7
|
Madjene LC, Danelli L, Dahdah A, Vibhushan S, Bex-Coudrat J, Pacreau E, Vaugier C, Claver J, Rolas L, Pons M, Madera-Salcedo IK, Beghdadi W, El Ghoneimi A, Benhamou M, Launay P, Abrink M, Pejler G, Moura IC, Charles N, Daugas E, Perianin A, Blank U. Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment. Kidney Int 2019; 97:516-527. [PMID: 31866111 DOI: 10.1016/j.kint.2019.08.037] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 08/20/2019] [Accepted: 08/29/2019] [Indexed: 12/22/2022]
Abstract
Here we investigated the role of murine mast cell protease 4 (MCPT4), the functional counterpart of human mast cell chymase, in an experimental model of renal ischemia reperfusion injury, a major cause of acute kidney injury. MCPT4-deficient mice had worsened kidney function compared to wildtype mice. MCPT4 absence exacerbated pathologic neutrophil infiltration in the kidney and increased kidney myeloperoxidase expression, cell death and necrosis. In kidneys with ischemia reperfusion injury, when compared to wildtype mice, MCPT4-deficient mice showed increased surface expression of adhesion molecules necessary for leukocyte extravasation including neutrophil CD162 and endothelial cell CD54. In vitro, human chymase mediated the cleavage of neutrophil expressed CD162 and also CD54, P- and E-Selectin expressed on human glomerular endothelial cells. MCPT4 also dampened systemic neutrophil activation after renal ischemia reperfusion injury as neutrophils expressed more CD11b integrin and produced more reactive oxygen species in MCPT4-deficient mice. Accordingly, after renal injury, neutrophil migration to an inflammatory site distal from the kidney was increased in MCPT4-deficient versus wildtype mice. Thus, contrary to the described overall aggravating role of mast cells, one granule-released mediator, the MCPT4 chymase, exhibits a potent anti-inflammatory function in renal ischemia reperfusion injury by controlling neutrophil extravasation and activation thereby limiting associated damage.
Collapse
Affiliation(s)
- Lydia Celia Madjene
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Luca Danelli
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Albert Dahdah
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Shamila Vibhushan
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Julie Bex-Coudrat
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Emeline Pacreau
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Celine Vaugier
- INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France; Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Laboratory of Excellence GR-Ex, Paris, France; CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France
| | - Julien Claver
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Loïc Rolas
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Maguelonne Pons
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Iris Karina Madera-Salcedo
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Walid Beghdadi
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Alaa El Ghoneimi
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France; Department of Pediatric Surgery and Urology, Hopital Robert Debré, APHP, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Marc Benhamou
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Pierre Launay
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Magnus Abrink
- Immunology Section, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, VHC, Uppsala, Sweden
| | - Gunnar Pejler
- Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
| | - Ivan Cruz Moura
- INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France; Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Laboratory of Excellence GR-Ex, Paris, France; CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France
| | - Nicolas Charles
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Eric Daugas
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France; Service de Néphrologie, Hôpital Universitaire Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Axel Perianin
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Ulrich Blank
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France.
| |
Collapse
|
8
|
Frossi B, Mion F, Sibilano R, Danelli L, Pucillo CEM. Is it time for a new classification of mast cells? What do we know about mast cell heterogeneity? Immunol Rev 2019; 282:35-46. [PMID: 29431204 DOI: 10.1111/imr.12636] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Mast cells (MCs) are derived from committed precursors that leave the hematopoietic tissue, migrate in the blood, and colonize peripheral tissues where they terminally differentiate under microenvironment stimuli. They are distributed in almost all vascularized tissues where they act both as immune effectors and housekeeping cells, contributing to tissue homeostasis. Historically, MCs were classified into 2 subtypes, according to tryptic enzymes expression. However, MCs display a striking heterogeneity that reflects a complex interplay between different microenvironmental signals delivered by various tissues, and a differentiation program that decides their identity. Moreover, tissue-specific MCs show a trained memory, which contributes to shape their function in a specific microenvironment. In this review, we summarize the current state of our understanding of MC heterogeneity that reflects their different tissue experiences. We describe the discovery of unique cell molecules that can be used to distinguish specific MC subsets in vivo, and discuss how the improved ability to recognize these subsets provided new insights into the biology of MCs. These recent advances will be helpful for the understanding of the specific role of individual MC subsets in the control of tissue homeostasis, and in the regulation of pathological conditions such as infection, autoimmunity, and cancer.
Collapse
Affiliation(s)
- Barbara Frossi
- Department of Medicine, University of Udine, Udine, Italy
| | - Francesca Mion
- Department of Medicine, University of Udine, Udine, Italy
| | - Riccardo Sibilano
- Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
| | - Luca Danelli
- Retroviral Immunology, The Francis Crick Institute, London, UK
| | | |
Collapse
|
9
|
Meng XM. Inflammatory Mediators and Renal Fibrosis. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2019; 1165:381-406. [PMID: 31399975 DOI: 10.1007/978-981-13-8871-2_18] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Renal inflammation is the initial, healthy response to renal injury. However, prolonged inflammation promotes the fibrosis process, which leads to chronic pathology and eventually end-stage kidney disease. There are two major sources of inflammatory cells: first, bone marrow-derived leukocytes that include neutrophils, macrophages, fibrocytes and mast cells, and second, locally activated kidney cells such as mesangial cells, podocytes, tubular epithelial cells, endothelial cells and fibroblasts. These activated cells produce many profibrotic cytokines and growth factors that cause accumulation and activation of myofibroblasts, and enhance the production of the extracellular matrix. In particular, activated macrophages are key mediators that drive acute inflammation into chronic kidney disease. They produce large amounts of profibrotic factors and modify the microenvironment via a paracrine effect, and they also transdifferentiate to myofibroblasts directly, although the origin of myofibroblasts in the fibrosing kidney remains controversial. Collectively, understanding inflammatory cell functions and mechanisms during renal fibrosis is paramount to improving diagnosis and treatment of chronic kidney disease.
Collapse
Affiliation(s)
- Xiao-Ming Meng
- School of Pharmacy, Anhui Medical University, Hefei, Anhui, China.
| |
Collapse
|
10
|
Ngo Nyekel F, Pacreau E, Benadda S, Msallam R, Åbrink M, Pejler G, Davoust J, Benhamou M, Charles N, Launay P, Blank U, Gautier G. Mast Cell Degranulation Exacerbates Skin Rejection by Enhancing Neutrophil Recruitment. Front Immunol 2018; 9:2690. [PMID: 30515167 PMCID: PMC6255985 DOI: 10.3389/fimmu.2018.02690] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 10/31/2018] [Indexed: 12/16/2022] Open
Abstract
Recent evidences indicate an important role of tissue inflammatory responses by innate immune cells in allograft acceptance and survival. Here we investigated the role of mast cells (MC) in an acute male to female skin allograft rejection model using red MC and basophil (RMB) mice enabling conditional MC depletion. Kinetic analysis showed that MCs markedly accelerate skin rejection. They induced an early inflammatory response through degranulation and boosted local synthesis of KC, MIP-2, and TNF. This enhanced early neutrophil infiltration compared to a female-female graft-associated repair response. The uncontrolled neutrophil influx accelerated rejection as antibody-mediated depletion of neutrophils delayed skin rejection. Administration of cromolyn, a MC stabilizer and to a lesser extent ketotifen, a histamine type I receptor antagonist, and absence of MCPT4 chymase also delayed graft rejection. Together our data indicate that mediators contained in secretory granules of MC promote an inflammatory response with enhanced neutrophil infiltration that accelerate graft rejection.
Collapse
Affiliation(s)
- Flavie Ngo Nyekel
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Emeline Pacreau
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Samira Benadda
- INSERM UMRS 1149, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Rasha Msallam
- Institut Necker Enfants Malades, INSERM U1151, CNRS, UMR8253, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
| | - Magnus Åbrink
- Section of Immunology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, VHC, Uppsala, Sweden
| | - Gunnar Pejler
- Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.,Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
| | - Jean Davoust
- Institut Necker Enfants Malades, INSERM U1151, CNRS, UMR8253, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Marc Benhamou
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Nicolas Charles
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Pierre Launay
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Ulrich Blank
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| | - Gregory Gautier
- INSERM UMRS 1149, Paris, France.,CNRS ERL8252, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Laboratoire D'excellence INFLAMEX, Paris, France
| |
Collapse
|
11
|
Oliveira-Silva GLD, Morais IBDM, Fortunato-Silva J, Alvarez MMP, França-Silva N, Galo JA, Hiraki KRN, Balbi APC, Bispo-da-Silva LB. Testosterone and Mast Cell Interactions in the Development of Kidney Fibrosis after Unilateral Ureteral Obstruction in Rats. Biol Pharm Bull 2018; 41:1164-1169. [PMID: 30068865 DOI: 10.1248/bpb.b17-00829] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Mast cell and testosterone interactions involved in renal fibrosis in rats subjected to unilateral ureteral obstruction (UUO) were investigated. Orchiectomized (ORX) and nonorchiectomized Wistar rats were subjected to UUO, and a nonorchiectomized group was sham-operated (control: SO). Animals from the UUO group were treated with saline or sodium cromoglycate (CG). Some ORX rats from the saline or CG groups also received testosterone propionate replacement (TR). Kidneys and blood were collected 14 d after UUO or SO. Kidney sections were stained with toluidine blue to quantify mast cells, and picrosirius red was used for collagen analysis. Immunohistochemistry for α-smooth muscle actin (α-SMA) and proliferating cell nuclear antigen (PCNA) expression was also performed. Plasma testosterone levels (PTLs) were measured. ORX decreased and TR normalized PTLs. UUO increased mast cell density in the kidney pelvis, but not in the kidney parenchyma. UUO increased mast cell degranulation, and CG or ORX inhibited this effect. TR partially reversed the effect of ORX on mast cell degranulation, and CG partially inhibited that effect of TR. UUO increased the collagen areas of the renal parenchyma, whereas CG or ORX abolished that alteration; TR reversed the effects of ORX, and CG partially inhibited that effect of TR. UUO increased tubulointerstitial α-SMA expression and PCNA-positive cells, and these changes were sensitive to ORX or CG to the same degree, while TR again reversed the effect of ORX. Renal fibrosis after UUO appears to be determined by interactions between testosterone and mast cells.
Collapse
Affiliation(s)
| | | | | | | | - Nathane França-Silva
- Department of Physiology Institute of Biomedical Sciences, Federal University of Uberlândia
| | - José Antônio Galo
- Department of Physiology Institute of Biomedical Sciences, Federal University of Uberlândia
| | - Karen Renata Nakamura Hiraki
- Department of Cell Biology, Histology and Embryology, Institute of Biomedical Sciences, Federal University of Uberlândia
| | - Ana Paula Coelho Balbi
- Department of Physiology Institute of Biomedical Sciences, Federal University of Uberlândia
| | | |
Collapse
|
12
|
Pons M, Leporq B, Ali L, Alison M, Albuquerque M, Peuchmaur M, Poli Mérol ML, Blank U, Lambert SA, El Ghoneimi A. Renal parenchyma impairment characterization in partial unilateral ureteral obstruction in mice with intravoxel incoherent motion-MRI. NMR IN BIOMEDICINE 2018; 31:e3858. [PMID: 29178439 DOI: 10.1002/nbm.3858] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 08/19/2017] [Accepted: 10/11/2017] [Indexed: 06/07/2023]
Abstract
Ureteropelvic junction obstruction constitutes a major cause of progressive pediatric renal disease. The biological mechanisms underlying the renal response to obstruction can be investigated using a clinically relevant mouse model of partial unilateral ureteral obstruction (pUUO). Renal function and kidney morphology data can be evaluated using renal ultrasound, scintigraphy and uro-magnetic resonance imaging (uro-MRI), but these methods are poorly linked to histological change and not all are quantitative. Here, we propose to investigate pUUO for the first time using an intravoxel incoherent motion diffusion sequence. The aim of this study was to quantitatively characterize impairment of the kidney parenchyma in the pUUO model. This quantitative MRI method was able to assess the perfusion and microstructure of the kidney without requiring the injection of a contrast agent. The results suggest that a perfusion fraction (f) reduction is associated with a decrease in the volume of the renal parenchyma, which could be related to decreased renal vascularization. The latter may occur before impairment by fibrosis and the findings are in accordance with the literature using the UUO mice model and, more specifically, on pUUO. Further investigation is required before this technique can be made available for the diagnosis and management of children with antenatal hydronephrosis and to select the optimal timing of surgery if required.
Collapse
Affiliation(s)
- Maguelonne Pons
- INSERM UMR 1149, Paris, France
- CNRS ERL8252, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Benjamin Leporq
- INSERM UMR 1149, Paris, France
- CNRS ERL8252, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Laboratoire d'excellence INFLAMEX, Paris, France
- Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Lyon, France
| | - Liza Ali
- INSERM UMR 1149, Paris, France
- CNRS ERL8252, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Laboratoire d'excellence INFLAMEX, Paris, France
- Department of Pediatric Surgery and Urology, Hôpital Robert Debré, APHP, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Marianne Alison
- Department of Pediatric Radiology, Hôpital Robert Debré, APHP, Université Paris Diderot, PRES Sorbonne Paris-Cité, INSERM U1141, DHU PROTECT, Paris, France
| | | | - Michel Peuchmaur
- Department of Pathology, Hôpital Robert Debré, APHP, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | | - Ulrich Blank
- INSERM UMR 1149, Paris, France
- CNRS ERL8252, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Simon A Lambert
- INSERM UMR 1149, Paris, France
- CNRS ERL8252, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Laboratoire d'excellence INFLAMEX, Paris, France
- Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Lyon, France
| | - Alaa El Ghoneimi
- INSERM UMR 1149, Paris, France
- CNRS ERL8252, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Laboratoire d'excellence INFLAMEX, Paris, France
- Department of Pediatric Surgery and Urology, Hôpital Robert Debré, APHP, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
13
|
Boyer HG, Wils J, Renouf S, Arabo A, Duparc C, Boutelet I, Lefebvre H, Louiset E. Dysregulation of Aldosterone Secretion in Mast Cell–Deficient Mice. Hypertension 2017; 70:1256-1263. [DOI: 10.1161/hypertensionaha.117.09746] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Revised: 06/08/2017] [Accepted: 09/20/2017] [Indexed: 02/06/2023]
Affiliation(s)
- Hadrien-Gaël Boyer
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Julien Wils
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Sylvie Renouf
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Arnaud Arabo
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Céline Duparc
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Isabelle Boutelet
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Hervé Lefebvre
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| | - Estelle Louiset
- From the Normandie Université, UNIROUEN, INSERM U1239, Rouen, France (H.-G.B., J.W., S.R., C.D., I.B., H.L., E.L.); Department of Pharmacology, Institute for Biomedical Research, Rouen University Hospital, France (J.W.); Normandie Université, UNIROUEN, Rouen, France (A.A.); and Department of Endocrinology, Diabetes, and Metabolic Diseases, Institute for Research and Innovation in Biomedicine, University Hospital of Rouen, France (H.L.)
| |
Collapse
|
14
|
Zeng H, He Y, Yu Y, Zhang J, Zeng X, Gong F, Liu Q, Yang B. Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis by mast cell suppression. Mol Med Rep 2017; 17:918-924. [PMID: 29115491 PMCID: PMC5780169 DOI: 10.3892/mmr.2017.7960] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 09/14/2017] [Indexed: 12/13/2022] Open
Abstract
Voiding dysfunction is the primary clinical manifestation of chronic prostatitis (CP), which is a common urological disease. The present study investigated whether prostate fibrosis was associated with urinary dysfunction in CP and if resveratrol improved urinary dysfunction, and the underlying molecular mechanism. A rat model of CP was established via subcutaneous injections of the pertussis-diphtheria-tetanus vaccine, which was followed by treatment with resveratrol. Bladder pressure and volume tests were performed to investigate the effect of resveratrol on urinary dysfunction in CP rats. Western blotting and immunohistochemical staining examined the expression levels of tryptase, chymase, transforming growth factor (TGF)-β, Wnt and α-smooth muscle actin (α-SMA). The results demonstrated that the maximum capacity of the bladder, residual urine volume and maximum voiding pressure were increased significantly in the CP group compared with the control group. Mast cell (MC) activation, the activity of TGF-β/Wnt/β-catenin pathways, and the expression levels of tryptase and α-SMA in the CP group were increased significantly compared with the control group. Resveratrol treatment significantly reversed these factors. Therefore, the results indicate that MC infiltration may induce prostate fibrosis, which exhibits a close association with urinary dysfunction in CP. Resveratrol may improve fibrosis via the suppression of MC activation and TGF-β/Wnt/β-catenin pathway activities.
Collapse
Affiliation(s)
- Huizhi Zeng
- Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Yi He
- Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Yang Yu
- Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Jiashu Zhang
- College of Pharmacy, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Xiaona Zeng
- College of Pharmacy, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Fengtao Gong
- College of Pharmacy, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Qi Liu
- College of Pharmacy, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| | - Bo Yang
- Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, P.R. China
| |
Collapse
|